247 related articles for article (PubMed ID: 27835884)
1. Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.
Tury S; Becette V; Assayag F; Vacher S; Benoist C; Kamal M; Marangoni E; Bièche I; Lerebours F; Callens C
Oncotarget; 2016 Dec; 7(51):85124-85141. PubMed ID: 27835884
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
3. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
4.
DE Cremoux P; Hamy AS; Lehmann-Che J; Scott V; Sigal B; Mathieu MC; Bertheau P; Guinebretière JM; Pierga JY; Giacchetti S; Brain E; Marty M; Asselain B; Spyratos F; Bièche I
Anticancer Res; 2018 Mar; 38(3):1485-1490. PubMed ID: 29491076
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.
Chia SKL; Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Kim SB; Jakobsen EH; Harvey V; Robert N; Smith J; Harker G; Zhang B; Eli LD; Ye Y; Lalani AS; Buyse M; Chan A
Breast Cancer Res; 2019 Mar; 21(1):39. PubMed ID: 30867034
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
[TBL] [Abstract][Full Text] [Related]
7. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
[TBL] [Abstract][Full Text] [Related]
9. LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.
Ramirez-Ardila DE; Ruigrok-Ritstier K; Helmijr JC; Look MP; van Laere S; Dirix L; Berns EM; Jansen MP
Mol Oncol; 2016 Oct; 10(8):1363-73. PubMed ID: 27491861
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.
Shimoi T; Hamada A; Yamagishi M; Hirai M; Yoshida M; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Kinoshita T; Fukuda T; Fujiwara Y; Tamura K
Cancer Sci; 2018 Aug; 109(8):2558-2566. PubMed ID: 29906308
[TBL] [Abstract][Full Text] [Related]
12. Frequency and spectrum of PIK3CA somatic mutations in breast cancer.
Martínez-Sáez O; Chic N; Pascual T; Adamo B; Vidal M; González-Farré B; Sanfeliu E; Schettini F; Conte B; Brasó-Maristany F; Rodríguez A; Martínez D; Galván P; Rodríguez AB; Martinez A; Muñoz M; Prat A
Breast Cancer Res; 2020 May; 22(1):45. PubMed ID: 32404150
[TBL] [Abstract][Full Text] [Related]
13. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
14.
Cho YA; Ko SY; Suh YJ; Kim S; Park JH; Park HR; Seo J; Choi HG; Kang HS; Lim H; Park HY; Kwon MJ
Curr Oncol; 2022 Apr; 29(5):2895-2908. PubMed ID: 35621626
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer.
Wang L; Chen W; Xie X; He Y; Bai X
Exp Oncol; 2008 Mar; 30(1):42-51. PubMed ID: 18438340
[TBL] [Abstract][Full Text] [Related]
16. EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma.
Moon A; Chin S; Kim HK; Kwak JJ; Koh ES; Kim YW; Jang KT
Pathology; 2016 Jan; 48(1):35-40. PubMed ID: 27020207
[TBL] [Abstract][Full Text] [Related]
17. COX-2 expression in chondrosarcoma: a role for celecoxib treatment?
Schrage YM; Machado I; Meijer D; Briaire-de Bruijn I; van den Akker BE; Taminiau AH; Kalinski T; Llombart-Bosch A; Bovée JV
Eur J Cancer; 2010 Feb; 46(3):616-24. PubMed ID: 20004565
[TBL] [Abstract][Full Text] [Related]
18. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
Karapetis CS; Jonker D; Daneshmand M; Hanson JE; O'Callaghan CJ; Marginean C; Zalcberg JR; Simes J; Moore MJ; Tebbutt NC; Price TJ; Shapiro JD; Pavlakis N; Gibbs P; Van Hazel GA; Lee U; Haq R; Virk S; Tu D; Lorimer IA;
Clin Cancer Res; 2014 Feb; 20(3):744-53. PubMed ID: 24218517
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer.
Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X
J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]